Powell Investment Advisors LLC Makes New Investment in UiPath Inc. (NYSE:PATH)

Powell Investment Advisors LLC acquired a new stake in shares of UiPath Inc. (NYSE:PATH) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 16,190 shares of the healthcare company’s stock, valued at approximately $402,000.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. grew its position in shares of UiPath by 7.6% during the 3rd quarter. Vanguard Group Inc. now owns 37,750,773 shares of the healthcare company’s stock valued at $645,916,000 after acquiring an additional 2,673,718 shares during the period. BlackRock Inc. boosted its holdings in UiPath by 32.1% in the 2nd quarter. BlackRock Inc. now owns 23,376,854 shares of the healthcare company’s stock worth $387,354,000 after buying an additional 5,681,577 shares during the period. FMR LLC boosted its holdings in UiPath by 2.9% in the 3rd quarter. FMR LLC now owns 16,238,176 shares of the healthcare company’s stock worth $277,835,000 after buying an additional 463,032 shares during the period. Goldman Sachs Group Inc. boosted its holdings in UiPath by 37.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 11,662,087 shares of the healthcare company’s stock worth $193,241,000 after buying an additional 3,172,300 shares during the period. Finally, Altimeter Capital Management LP boosted its holdings in UiPath by 175.4% in the 1st quarter. Altimeter Capital Management LP now owns 8,275,000 shares of the healthcare company’s stock worth $71,579,000 after buying an additional 5,270,194 shares during the period. Institutional investors own 62.50% of the company’s stock.

Analyst Ratings Changes

PATH has been the subject of several recent analyst reports. Evercore ISI upped their target price on shares of UiPath from $24.00 to $27.00 and gave the stock an “in-line” rating in a report on Thursday, March 14th. Royal Bank of Canada reissued a “sector perform” rating and set a $29.00 price objective on shares of UiPath in a report on Monday, April 1st. Wells Fargo & Company increased their price objective on shares of UiPath from $24.00 to $25.00 and gave the company an “equal weight” rating in a report on Thursday, March 14th. Scotiabank increased their price objective on shares of UiPath from $29.00 to $30.00 and gave the company a “sector perform” rating in a report on Thursday, March 14th. Finally, Barclays increased their price objective on shares of UiPath from $23.00 to $25.00 and gave the company an “equal weight” rating in a report on Friday, March 15th. Nine equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $27.41.

Insiders Place Their Bets

In other news, CFO Ashim Gupta sold 16,000 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $22.84, for a total transaction of $365,440.00. Following the transaction, the chief financial officer now directly owns 87,505 shares of the company’s stock, valued at $1,998,614.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 72,000 shares of company stock valued at $1,591,360 over the last 90 days. Insiders own 31.03% of the company’s stock.

UiPath Stock Performance

NYSE PATH traded down $0.29 during trading on Friday, hitting $18.75. The stock had a trading volume of 5,614,037 shares, compared to its average volume of 5,784,653. The stock has a market capitalization of $10.67 billion, a price-to-earnings ratio of -110.23 and a beta of 0.96. UiPath Inc. has a one year low of $12.38 and a one year high of $27.87. The stock has a 50 day simple moving average of $22.82 and a 200 day simple moving average of $21.45.

UiPath (NYSE:PATH) last announced its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.10. The business had revenue of $405.25 million during the quarter, compared to the consensus estimate of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. On average, sell-side analysts predict that UiPath Inc. will post -0.04 EPS for the current year.

UiPath Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.